Analysts Expect XOMA Corp (NASDAQ:XOMA) to Announce -$0.48 Earnings Per Share

Share on StockTwits

Equities research analysts expect XOMA Corp (NASDAQ:XOMA) to report earnings per share of ($0.48) for the current quarter, Zacks reports. Two analysts have made estimates for XOMA’s earnings, with the highest EPS estimate coming in at ($0.26) and the lowest estimate coming in at ($0.67). XOMA posted earnings of ($0.55) per share during the same quarter last year, which indicates a positive year over year growth rate of 12.7%. The business is expected to report its next quarterly earnings report on Wednesday, November 6th.

According to Zacks, analysts expect that XOMA will report full-year earnings of ($1.15) per share for the current year, with EPS estimates ranging from ($1.40) to ($0.75). For the next financial year, analysts forecast that the firm will report earnings of ($1.55) per share, with EPS estimates ranging from ($2.51) to ($0.90). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that cover XOMA.

XOMA (NASDAQ:XOMA) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.07. XOMA had a negative net margin of 72.20% and a negative return on equity of 51.91%. The business had revenue of $0.96 million during the quarter, compared to analyst estimates of $0.63 million.

A number of equities research analysts have recently issued reports on the stock. Wedbush reissued a “buy” rating and set a $25.00 price objective on shares of XOMA in a research report on Wednesday, August 7th. ValuEngine downgraded shares of XOMA from a “buy” rating to a “hold” rating in a research report on Tuesday, August 6th. Finally, HC Wainwright set a $30.00 price objective on shares of XOMA and gave the company a “buy” rating in a research report on Friday, June 14th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $27.50.

Several hedge funds have recently modified their holdings of the company. Marshall Wace LLP bought a new position in XOMA in the 2nd quarter worth $434,000. Morgan Stanley boosted its holdings in XOMA by 2,151.6% in the 2nd quarter. Morgan Stanley now owns 23,889 shares of the biotechnology company’s stock worth $355,000 after buying an additional 22,828 shares during the period. Paloma Partners Management Co bought a new position in XOMA in the 2nd quarter worth $510,000. Stonepine Capital Management LLC boosted its holdings in shares of XOMA by 18.9% during the 2nd quarter. Stonepine Capital Management LLC now owns 270,449 shares of the biotechnology company’s stock valued at $4,019,000 after purchasing an additional 43,019 shares during the last quarter. Finally, Athanor Capital LP bought a new position in shares of XOMA during the 2nd quarter valued at about $149,000. 47.63% of the stock is owned by hedge funds and other institutional investors.

Shares of XOMA stock traded down $0.22 during mid-day trading on Thursday, reaching $16.47. 51,996 shares of the company’s stock traded hands, compared to its average volume of 63,860. XOMA has a 12 month low of $11.02 and a 12 month high of $20.29. The firm’s 50 day moving average price is $17.10. The company has a quick ratio of 3.90, a current ratio of 3.90 and a debt-to-equity ratio of 1.39. The stock has a market cap of $151.29 million, a price-to-earnings ratio of -10.36 and a beta of 1.29.

XOMA Company Profile

XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.

Featured Article: Why do earnings reports matter?

Get a free copy of the Zacks research report on XOMA (XOMA)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for XOMA (NASDAQ:XOMA)

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with's FREE daily email newsletter.